Maynard Um
-
-
-
-
-
-
-
Outlook Therapeutics submits drug approval dispute to FDA
-
-
-
-
-
-
-
Outlook Therapeutics Inc. (OTLK) PT Lowered to $0.50 at H.C. Wainwright
-
-
-
-
-
-
-
Outlook Therapeutics Incs. (OTLK) PT Raised to $13 at Brookline Capital Markets
-
-
-
-
-
-
-
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
-
-
-
-
-
-
-
Outlook Therapeutics (OTLK) propses public offering
-
-
-
-
-
-
-
Outlook Therapeutics (OTLK) Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Outlook Therapeutics Incs. (OTLK)
-
404,873 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

